Chronic illnesses are associated with an increased risk of depression and anxiety. Rheumatoid arthritis (RA) is a chronic autoimmune disease that typically causes damage to the joints. RA extensively impacts patients, both physically and psychologically. Depression is a common comorbid disorder with RA, which leads to worsened health outcomes. There are several cytokines that are active in the joints of patients with RA. Inflammatory cytokines serve important roles in the key processes in the joints, which usually cause inflammation, articular damage and other comorbidities associated with RA. The key role of inflammatory cytokines could be attributed to their interactions within signaling pathways. In RA, IL-1, and the cytokines of TNF-α, IL-6 and IL-18 are primarily involved. Furthermore, depression is hypothesized to be strongly associated with systemic inflammation, particularly with dysregulation of the cytokine network. The present review summarizes the current state of knowledge on these two diseases from the perspective of inflammation and cytokines, and emphasizes the possible bridge between them by exploring the involvement of systemic cytokines in both conditions.
rheumatoid arthritisinflammatory cytokinesdepressioncytokine network1. Rheumatoid arthritis and depression
Rheumatoid arthritis (RA) is a chronic autoimmune disease that typically causes damage to the joints. The disease primarily targets the synovial membrane, cartilage and bone. As a systemic inflammatory disease, RA also affects other tissues and organs, and is thus associated with progressive disability, potential systemic complications, high socioeconomic costs, and early death worldwide (1). Although, there have been advances in the understanding of the pathogenesis of RA, the cause of RA remains elusive (1). The pathogenesis of RA is complex and involves large numbers of different cell types and signaling pathways (2). It is widely accepted that autoimmune processes and cytokines may serve important roles in the initiation and perpetuation of the disease (3,4). Among these, TNF, IL-6 and IL-1 are the best studied, and are further discussed in the following section. The current strategies for treatment of RA include symptomatic management and early disease therapy (5). As RA is an inflammatory disease, medications that suppress inflammation, such as non-steroidal anti-inflammatory drugs and glucocorticoids are frequently used as first-line therapeutic agents for treatment of the symptoms (6). During the last decade, disease-modifying antirheumatic drugs (DMARDs) were introduced as an important therapeutic strategy due their effect on the binding of pro-inflammatory cytokines to their corresponding receptors (7), and these should be initiated as soon as RA is diagnosed (8). The most commonly used biological DMARDs in RA therapy include inhibitors of TNF-α (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol), IL-1 inhibitors, anti-IL-6 receptor monoclonal antibody (tocilizumab), the T-cell signaling inhibitor (abatacept) and the chimeric anti-CD20 monoclonal antibody (rituximab) (9). Patients started on combined treatment of conventional synthetic DMARDs with biological DMARDs in earlier stages showed obvious clinical improvement and less damage to the joints in the BeSt study (10).
Depression and anxiety are frequent comorbidities in patients with RA and it has been shown that they may occur in up to 42% in RA patients (11). It is estimated that ~30% of patients with RA develop depression within 5 years of being diagnosed (12). Depression significantly and synergistically contributes to increased mortality and morbidity in patients with RA, and also increases health care costs for the health system (13). Inflammatory networks and cytokines may constitute a link between depression and RA. The co-occurrence of depression in RA is significantly associated with age, and younger patients show a higher risk of developing depression compared with older patients (12). Low self-esteem is among the strongest predictors in patients with RA who may eventually end up with depression (12). During the past two decades, the reciprocal communication between the central nervous system (CNS), endocrine system and immune system has been well established (14). Some of the psychiatric diseases, including depression, are hypothesized to be closely associated with systemic inflammation and cytokines. Therefore, exploring the common functions that may be shared by RA and depression will both broaden the horizon of basic research in these two fields and may also provide theoretical support for the clinical treatment of RA with a systemic view.
The aim of this review is to discuss the biological contribution and potential therapeutic targets of the major cytokine families in the aetiology of RA and depression, and summarize the complex pathophysiology of this disease with a focus on cytokines, including TNF-α, IL-6 and IL-1 and their families and relevant signaling pathways. Furthermore, the therapeutic agents that are presently utilized in both of the diseases, along with potential therapeutic targets are reviewed. Additionally, how an improved understanding of the role of cytokines and signaling pathways in these two diseases may help the development of novel therapeutic strategies with specific targets is briefly discussed.
2. Immunological pathology of RA
Major histocompatibility complex (MHC) is considered a key factor associated with a predisposition to RA (15). Outside of the MHC region, additional risk loci have been identified and validated including PTPN22, STAT4, PADI4, CTLA4 and FcγRs, as well as various cytokine and cytokine-receptor loci. Several immune modulators (cytokines and effector cells) and signaling pathways involved in the pathophysiology of RA have been revealed. The complex interactions between the inflammatory cytokines are responsible for joint damage that is initiated at the synovial membrane and then progresses to other structures of the joint. There is extensive activation of monocytes, macrophages, and synovial fibroblasts, as well as overproduction of pro-inflammatory cytokines, such as IL-1, IL-6 and TNF-α amongst others (16). There are other cytokines and chemokines that are also found in the synovial membrane, such as IL-15, IL-17 and IL-18. These inflammatory cytokines activate several signaling pathways and induce transcription of the genes, which are key factors involved in inflammation and tissue degradation (17). Due to the important roles of inflammatory cytokines in RA, there has been increasing interest in how the inflammatory cytokines within a complex regulatory network are associated with disease progression of RA.
3. Inflammatory cytokines in RA
Inflammatory cytokines are responsible for stimulating destructive mechanisms in the joint which results in structural injury and subsequently leads to a functional decline in mobility and disability.
Role of IL-1 and IL-18 in RA
IL-1 is an important inflammatory factor that is involved in the pathogenesis of RA. IL-1 induces an inflammatory response and activates or increases the expression of other pro-inflammatory mediators that promote damage to the joints (18). In the synovial membrane, IL-1 and IL-1 receptor antagonists are abundantly expressed (18). IL-1 activation causes migration of inflammatory cells to the joints and the synovium in patients with RA. Then, macrophages, lymphocytes, monocytes and transformed fibroblasts are triggered to produce increased quantities of IL-1, which contributes to the production and secretion of various cellular messengers (19). Regulatory agents, such as proteoglycans and proteases contribute to the formation and accumulation of pannus in the joints, resulting in the erosion of the cartilage and bone, fibrosis, and ultimately articular function loss (20). At the cellular level, there are several other cytokines induced by IL-1, including TNF-α and IL-6(18). As the key pro-inflammatory cytokines in RA, IL-1 and TNF-α act synergistically in promoting further inflammation and matrix damage to the arthritic joints (21). In an experimental animal model, IL-1 was shown to stimulate cartilage and bone re-absorption and inhibit articular collagen and proteoglycan synthesis (22). Experiments performed on RA animal models suggest that IL-1 serves a crucial role in the degradation of proteoglycans and thus increases joint damage (22,23). Local production of IL-1 was shown to inhibit proteoglycan synthesis in the knee joints of a collagen-induced arthritis (CIA) model (24). In addition, IL-6 in synovial cells can lead to the acceleration of joint breakdown by attracting and retaining large quantities of leukocytes in the inflamed synovium (25). In patients with RA, there are increased levels of IL-1 in the plasma and synovial fluid (26,27). The IL-1 family includes IL-1α and IL-1 and IL1 receptor antagonist (IL-1Ra). The biological activation of cells by IL-1 requires the expression of the type I IL-1 receptor (IL-1R). The receptor antagonist IL-1Ra, generated by certain cells in the joint, can competitively bind with IL-1R. As an anti-inflammatory protein that binds to IL-1R without transducing signals, IL-1Ra may, to some extent, regulate the activity of IL-1(18). It has been reported that IL-1Ra-deficient mice develop spontaneous arthritis, mediated through the amplification of Th17-dependent inflammation (28). IL-1Ra effectively attenuated joint destruction in an experimental RA model (29). There is a dysregulation of IL-1Ra production and inhibition of the effects of IL-1β in RA patients (30). IL-18, another member of the IL-1 cytokine superfamily, is widely detected in the synovium of patients with RA (18). The mRNA expression levels of IL-18 and IL-1β are differentially regulated. It has been found that IL-18 distributes in the synovial membrane with a different pattern compared with IL-1β. While IL-1β is localized primarily throughout the interstitium, lining layer and vasculature, IL-18 is highly expressed in lymphocytic aggregates (31). The expression of IL-18 in synovial tissues in vitro is associated with increased TNF-α and IL-1β, and the blockade of IL-18 by a neutralizing antibody was shown to ameliorate the disease in rodent RA models (32). IL-18 also contributes to cartilage degradation by affecting cell proliferation and the expression of matrix metalloproteinase and inducible NO synthase gene expression (33).
Role of IL-6 in RA
IL-6, which was initially identified as a B cell regulatory factor, is now recognized as a soluble mediator with a pleiotropic function on inflammation, immune response, and hematopoiesis (34). It serves important roles in RA pathogenesis via the activation and maturation of B and T cells, as well as the production of autoantibodies. IL-6 can stimulate B and T cell functions via promoting the proliferation of plasmablastic precursors in the bone marrow, maturating the immunoglobulin-producing plasma cells and through its role in T cell activation and proliferation (35). Although certain cytokines work on target cells that are close to their secretion site, IL-6 exerts its effects on distant target cells through ubiquitously expressed receptors. Classical IL-6 signaling requires a protein complex that includes a membrane-bound, non-signaling α-receptor unit (IL-6R) and two signal-transducing glycoprotein 130 (gp130) subunits (36). Conversely, IL-6 trans-signaling involves binding between a soluble receptor (sIL-6R) and membrane-bound gp130 subunits (36). As IL-6R expression is restricted to only a few cell types, trans-signaling leads to an increase in the range of IL-6-responsive cells (36). IL-6 trans-signaling is one of the major factors involved in the pathogenesis of RA. It is hypothesized that the increased IL-6 bioactivity is responsible for the local and systemic effects of RA. It seems that IL-6 acts as a major mediator of the acute phase response in RA (36). IL-6 is a 26-kDa pleiotropic cytokine, encoded on chromosome 7, and is produced by various cell types, including T cells and B cells (36). It has been reported that IL-6 is one of the most abundantly expressed inflammatory cytokines in the rheumatoid synovium (37). The concentration of IL-6 and sIL6R is correlated with the histological changes of chronic synovitis in patients with RA, while localized increases in sIL-6R are correlated with leukocyte infiltration (38). Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that promotes the migration and proliferation of endothelial cells (39). VEGF also induces vascular permeability and mediates inflammation. IL-6 was found to enhance joint inflammation and damage in patients with RA by affecting VEGF expression (40). IL-6 knockout mice were protected from CIA and exhibited reduced immune cell responses and tissue damage of knee joints (34,41). IL-6 receptor blocking can ameliorate joint disease in murine CIA (34).
Role of TNF-α in RA
TNF-α is a pleiotropic, pro-inflammatory cytokine and is considered to serve a key role in the pathophysiological processes of RA. TNF-α is a ligand of the TNF superfamily (42). TNF-α is inserted into the cell membrane, and the extracellular portion is subsequently released into circulation (43). There are two distinct membrane receptors that have been identified and cloned, namely TNF-R1 and TNF-R2. The apparent molecular weight between the two receptors varies because of the variation in glycosylation. These receptors can bind to both the soluble and membrane-bound forms of TNF-α (44). TNF-R1 is responsible for the majority of the cellular responses to TNF-α (44). The ubiquitous expression of TNF-R, along with cell-specific effector molecules triggered by TNF-R contribute to the various effects of TNF-α including apoptosis, the synthesis of protein and lipid inflammatory molecules, and transcription factors (45). TNF-α contributes to activation of other inflammatory cytokines, including IL-1, IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor (GM-CSF) (46). In an in vitro study, blocking TNF-α decreased the levels of IL-1, IL-6, IL-8, and GM-CSF in cultured synovial cells from RA patients (47). Thus, blockade of TNF-α may exert a more comprehensive effect on inflammation than other cytokines, such as IL-1, due to its high concentration in the synovial fluids. TNF-α is suggested to serve a key role in rheumatoid synovitis. In a CIA model, it was reported that TNF-α levels were elevated early in the disease course of CIA and persisted at high levels throughout the later stages (48). Mice with downregulated TNF-α expression developed chronic symmetric polyarthritis with histological features similar to that in human RA (49,50).
4. Anti-cytokine therapies in RA
Recent developments in understanding the role of cytokines in the pathological changes of RA, combined with biopharmaceutical progress, have facilitated the development of novel treatments.
Anti-TNF-α agents in RA
Studies have shown that blockade of TNF appears to be the major breakthrough in RA treatment, and that TNF-α antagonists significantly reduce the symptoms of RA in patients (51,52). Clinical studies have shown that the efficacy of the TNF inhibitors is at least comparable to methotrexate, which is one of the most effective medications currently used to treat RA (53). Long-term anti-TNF-α treatment reversed endothelial dysfunction in RA (54). A recent review indicated that TNF-α antagonists can ameliorate the progression of atherosclerosis and arterial changes (21,55). The drugs currently available in the clinical practice and clinical trials are biological protein-based drugs, such as antibodies to TNF-α or agents targeting TNF-α receptors (for example, linked to Fc dimers) (56). There are five TNF-α inhibitors that have been approved for treatment of RA, including infliximab, etanercept, adalimumab, certolizumab and golimumab (57,58). Their practical use has been limited by the need for repeated injections and other side effects (59). A recent large US observational study has also raised concerns regarding the risk of skin cancer with the use of biological therapy (60).
Anti-IL-1 agent in RA
Blocking of IL-1 has been considered as a potential strategy for treating RA. Anakinra, a recombinant form of human IL-1R antagonist, appears to inhibit the proinflammatory effect of IL-1(18). It is identical to the natural endogenous IL-1RA form (61). Due to its short half-life, daily injections are required. Anakinra decreases the migration of immune cells into the joint of patients with RA (62). In RA patients, joint damage is significantly attenuated following anakinra treatment (63). The most commonly observed adverse effect of anakinra is the susceptibility to infections and skin irritation at the injection site (64). However, due to the inconvenience of daily injections of anakinra and the superior clinical effects of other anti-cytokine therapies, anakinra is not used as a first-line treatment in RA (63,64).
Anti-IL-6 agent in RA
A monoclonal antibody, Tocilizumab (TCZ) binds to IL-6R and the binding subsequently blocks dimerization of the receptor complex, preventing IL-6 transmembrane signaling (65). The efficacy of TCZ in the treatment of RA has been confirmed in a few clinical trials (66,67). Reducing IL-6 activity in the inflammatory process of RA prevents inflammation of the joints, decreases damage, and reduces certain systemic symptoms (68,69). The erosion in joint and space narrowing were significantly decreased in TCZ treated patients compared with the DMARD treated group, suggesting that the inhibition of IL-6 was effective in both managing the symptoms and sustaining structural integrity of the joints (70). Similar to other disease modifying drugs, safety is always a major concern when investigating a new line of therapies (71). Further studies are required to examine the treatment benefits of TCZ therapy in RA treatment (68).
Upcoming therapies for RA
There are several potentially promising therapies targeting cytokines in RA which are being studied and may serve as suitable novel therapies for RA treatment. IL-18 may be a novel target for treating patients with RA. Recombinant IL-18 binding protein treatment abrogated disease severity (29), and treatment of anti-IL-18 in mice with collagen-induced arthritis exhibited similar results (29). IL-10 and IL-4 are cytokines with opposing-regulatory roles, both of which could downregulate pro-inflammatory responses. IL-10 and IL-4 are suggested to suppress the generation of inflammatory cytokines including IL-1, IL-6 and TNF-α in RA. A recent study on Janus kinase (JAK) inhibitors demonstrated that the JAK/STAT signalling pathway mediated cytokines important for disease by facilitating the downstream signaling cascade of cytokine receptors upon binding with their respective cytokines, such as by increasing transcription of certain genes (72). For example, tofacitinib, a typical JAK inhibitor that interferes with the JAK-STAT signaling pathway and mRNA transcription, is currently used for the treatment of RA. Previous studies have shown that stimulation with IFNs results in STAT activation (73,74). Table I summarizes the available anti-cytokine agents for treatment of RA.
5. Role of cytokines in depression: Mechanism and treatmentIL-6 in depression
It has previously been shown that IL-6 is associated with stress-related disorders, including depression and anxiety (75). A meta-analysis showed that IL-6 is the most significantly increased cytokine in the serum of depressed patients, and thus IL-6 levels in the serum may serve as a promising predictive biomarker for diagnosis of depression (75). Interestingly, a paediatric study found that peripheral inflammation predicted the occurrence of depression in younger patients (76). Children aged 9 with higher levels of IL-6 demonstrated a 10% increased likelihood of suffering depression at the age of 18 compared with children with lower levels of IL-6. This result suggests that monitoring the blood IL-6 levels in younger patients at a high risk of depression during the early stages may be used to implement measures which would prevent the progression of deterioration of a patient's mood. Furthermore, several monoclonal antibodies are currently in clinical trials for their use in the possible treatment of mood disorders, such as chimeric IL-6 receptor antibodies (Tocilizumab) or IL-6 antibodies (Siltuximab/Sirukumab) (75).
IL-1 in depression
It is well-established that the hippocampus is one of the key brain regions involved in the pathophysiology of depression (77). Stress and other environmental factors impact the functions of neurons in the hippocampus and influences depressive and anxiety-like phenotypes (77). Among the IL-1 cytokines, IL-1β is considered a key mediator responding to stressors, and it is widely expressed in the CNS, including the hypothalamus, hippocampus, and cerebral cortex. A previous study showed that the levels of IL-1β in the blood serum and in the cerebrospinal fluid are increased in patients with significantly more stressful lives and in patients who suffer from depression (78,79). Furthermore, the expression levels of IL-1β in peripheral blood circulation of patients with depression is correlated with the severity and duration of depression (77).
TNF-α in depression
Chronic illnesses induce the release of peripheral cytokines, which may result in cerebral endothelial leakage and then cause a neuroinflammatory reaction (80). The induced inflammatory response in the CNS is associated with the development of depression (81). TNF-α levels may be increased in patients who suffer from depression and is a potential biomarker for diagnosis of depression (82). In a pre-clinical study based on an animal model, deletion of TNF-α receptors was associated with antidepressant-like effects in behavioural tests compared with the wild-type counterparts (83). Additionally, a previous study showed that inhibiting the TNF-α signaling pathway may serve as a novel means of investigating how the CNS inflammatory response is associated with depression (81). Compounds targeting TNF-α signaling through inhibition of its downstream effectors exert anti-depressant and anti-anxiety-like effects in an animal model (81).
Other cytokines involved in depression
Interestingly, a recent study found that the antidepressant venlafaxine could ameliorate arthritis by targeting STAT3 and IL17(84). Clinical data has validated that IFN-γ levels are well correlated with clinical symptoms of depression in patients with glioma (85). Although there is no effort to explore whether IFN-γ activated the STAT cascade in depression, data have shown that IFN-α can activate JNK/STATs in a model of depression (86).
6. Conclusion
The pathogenesis of RA is complicated. It involves several immune cells and the interplay between numerous cytokines (Fig. 1) (87,88). Consequently, these cytokines further activate and promote differentiation of the downstream cells, which could result in local or systemic symptoms relevant to RA. For example, certain cytokines activate the JAK/STAT signaling pathway and initiate gene transcription of various other cytokines (Fig. 2) (89,90), and/or activate the SAPK/MAPK (Fig. 3) (91,92). Furthermore, depression is a frequently observed complication in patients with later stage RA. These two diseases may aggravate each other in via unknown mechanisms and afflict the patients further. This review focused on the inflammatory cytokines and signaling pathways which may serve as potential mediators of common pathways between RA and depression. One of the purposes of this review was to identify potential common therapeutic targets for both RA and depression treatment. With the encouraging preclinical and clinical data, there may be progress in therapeutic advancement targeting the unresolved clinical hurdles in RA with depression. To further elucidate the role of inflammation on the pathology of these diseases, and to design improved treatments, comprehensive analyses of mechanisms of action are necessary to optimise therapy with the ultimate focus of providing a cure for patients with these chronic illnesses. Additionally, RA is a chronic disease that is potentially devastating for a patient's quality of life and may result in mental disorders. Therefore, psychological factors may also be another key network responsible for the depression and other mood disorders in patients with RA.
Acknowledgements
Not applicable.
Funding
This review was supported by a Fellowship from China Scholarship Council for the support of his overseas research at the University of Manitoba (Canada).
Availability of data and materials
Not applicable.
Authors' contributions
CZ wrote and revised the manuscript. The author read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesBrennanFMMcInnesIBEvidence that cytokines play a role in rheumatoid arthritisJ Clin Invest1183537354520081898216010.1172/JCI36389UngethuemUHaeuplTWittHKoczanDKrennVHuberHvon HelversenTMDrungowskiMSeyfertCZacherJMolecular signatures and new candidates to target the pathogenesis of rheumatoid arthritisPhysiol Genomics42A26728220102085871410.1152/physiolgenomics.00004.2010NixonRBansbackNBrennanAThe efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: A meta-analysis and adjusted indirect comparisonsRheumatology (Oxford)461140114720071747847210.1093/rheumatology/kem072VerhoefLMvan den BemtBJvan der MaasAVriezekolkJEHulscherMEvan den HoogenFHJacobsWCvan HerwaardenNden BroederAADown-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activityCochrane Database Syst Rev5CD01045520193112544810.1002/14651858.CD010455.pub3UpchurchKSKayJEvolution of treatment for rheumatoid arthritisRheumatology (Oxford)51vi28vi3620122322158410.1093/rheumatology/kes278QuanLDThieleGMTianJWangDThe development of novel therapies for rheumatoid arthritisExpert Opin Ther Pat1872373820081957846910.1517/13543776.18.7.723O'DellJRTherapeutic strategies for rheumatoid arthritisN Engl J Med3502591260220041520141610.1056/NEJMra040226MoriSManagement of rheumatoid arthritis patients with interstitial lung disease: Safety of biological antirheumatic drugs and assessment of pulmonary fibrosisClin Med Insights Circ Respir Pulm Med9 (Suppl 1)S41S4920152640110110.4137/CCRPM.S23288KlarenbeekNBGüler-YükselMvan der KooijSMHanKHRondayHKKerstensPJSeysPEHuizingaTWDijkmansBAAllaartCFThe impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt studyAnn Rheum Dis701039104620112141505210.1136/ard.2010.141234InuiKKoikeTCombination therapy with biologic agents in rheumatic diseases: Current and future prospectsTher Adv Musculoskelet Dis819220220162772190510.1177/1759720X16665330BruceTOComorbid depression in rheumatoid arthritis: Pathophysiology and clinical implicationsCurr Psychiatry Rep1025826420081865279510.1007/s11920-008-0042-1JacobLRockelTKostevKDepression risk in patients with rheumatoid arthritis in the United KingdomRheumatol Ther419520020172832183310.1007/s40744-017-0058-2MargarettenMJulianLKatzPYelinEDepression in patients with rheumatoid arthritis: Description, causes and mechanismsInt J Clin Rheumtol661762320112221113810.2217/IJR.11.6SchiepersOJWichersMCMaesMCytokines and major depressionProg Neuropsychopharmacol Biol Psychiatry2920121720051569422710.1016/j.pnpbp.2004.11.003ViatteSPlantDRaychaudhuriSGenetics and epigenetics of rheumatoid arthritisNat Rev Rheumatol914115320132338155810.1038/nrrheum.2012.237McInnesIBSchettGCytokines in the pathogenesis of rheumatoid arthritisNat Rev Immunol742944220071752575210.1038/nri2094FiresteinGSEvolving concepts of rheumatoid arthritisNature42335636120031274865510.1038/nature01661KinneRWStuhlmüllerBBurmesterGRCells of the synovium in rheumatoid arthritis. MacrophagesArthritis Res Ther922420071817751110.1186/ar2333KinneRWBräuerRStuhlmüllerBPalombo-KinneEBurmesterGRMacrophages in rheumatoid arthritisArthritis Res218920220001109442810.1186/ar86HataHSakaguchiNYoshitomiHIwakuraYSekikawaKAzumaYKanaiCMoriizumiENomuraTNakamuraTSakaguchiSDistinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in miceJ Clin Invest11458258820041531469510.1172/JCI21795SchettGGravalleseEBone erosion in rheumatoid arthritis: Mechanisms, diagnosis and treatmentNat Rev Rheumatol865666420122300774110.1038/nrrheum.2012.153SilveiraKDCoelhoFMVieiraATBarrosoLCQueiroz-JuniorCMCostaVVSousaLFOliveiraMLBaderMSilvaTAMechanisms of the anti-inflammatory actions of the angiotensin type 1 receptor antagonist losartan in experimental models of arthritisPeptides46536320132372729110.1016/j.peptides.2013.05.012RuscittiPCiprianiPLiakouliVCarubbiFBerardicurtiODi BenedettoPCicciaFGugginoGAlvaroSTrioloGGiacomelliRThe emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetesRev Recent Clin Trials1321021420182954242210.2174/1574887113666180314102651ZouYZengSHuangMQiuQXiaoYShiMZhanZLiangLYangXXuHInhibition of 6-phosphofructo-2-kinase suppresses fibroblast-like synoviocytes-mediated synovial inflammation and joint destruction in rheumatoid arthritisBr J Pharmacol17489390820172823984610.1111/bph.13762BuckleyCDMichael Mason prize essay 2003. Why do leucocytes accumulate within chronically inflamed joints?Rheumatology (Oxford)421433144420031283271510.1093/rheumatology/keg413KayJCalabreseLThe role of interleukin-1 in the pathogenesis of rheumatoid arthritisRheumatology (Oxford)43 (Suppl 3)iii2iii920041515042610.1093/rheumatology/keh201ArendWPPalmerGGabayCIL-1, IL-18, and IL-33 families of cytokinesImmunol Rev223203820081861382810.1111/j.1600-065X.2008.00624.xNakaeSSaijoSHoraiRSudoKMoriSIwakuraYIL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonistProc Natl Acad Sci USA1005986599020031272136010.1073/pnas.1035999100AbramsonSBAminABlocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilageRheumatology (Oxford)4197298020021220902910.1093/rheumatology/41.9.972JacquesCGossetMBerenbaumFGabayCThe role of IL-1 and IL-1Ra in joint inflammation and cartilage degradationVitam Horm7437140320061702752410.1016/S0083-6729(06)74016-XLebreMCJongbloedSLTasSWSmeetsTJMcInnesIBTakPPRheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP-dendritic cells with distinct cytokine profilesAm J Pathol17294095020081829223410.2353/ajpath.2008.070703Plater-ZyberkCJoostenLAHelsenMMSattonnet-RochePSiegfriedCAlouaniSvan De LooFAGraberPAloniSCirilloRTherapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritisJ Clin Invest1081825183220011174826610.1172/JCI12097LotzMThe role of nitric oxide in articular cartilage damageRheum Dis Clin North Am2526928219991035641710.1016/s0889-857x(05)70067-3TanakaTNarazakiMKishimotoTIL-6 in inflammation, immunity, and diseaseCold Spring Harb Perspect Biol6a01629520142519007910.1101/cshperspect.a016295AlonziTFattoriELazzaroDCostaPProbertLKolliasGDe BenedettiFPoliVCilibertoGInterleukin 6 is required for the development of collagen-induced arthritisJ Exp Med1874614681998946339610.1084/jem.187.4.461KishimotoTInterleukin-6: From basic science to medicine-40 years in immunologyAnnu Rev Immunol2312120051577156410.1146/annurev.immunol.23.021704.115806NarazakiMTanakaTKishimotoTThe role and therapeutic targeting of IL-6 in rheumatoid arthritisExpert Rev Clin Immunol1353555120172849421410.1080/1744666X.2017.1295850MarrelliACiprianiPLiakouliVCarubbiFPerriconeCPerriconeRGiacomelliRAngiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?Autoimmun Rev1059559820112154585110.1016/j.autrev.2011.04.020JohnsonKEWilgusTAVascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repairAdv Wound Care (New Rochelle)364766120142530213910.1089/wound.2013.0517SokoloveJLepusCMRole of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretationsTher Adv Musculoskelet Dis5779420132364125910.1177/1759720X12467868Diaz-TorneCOrtizMDAMoyaPHernandezMVReinaDCastellviIDe AgustinJJFuenteDCorominasHSanmartiRThe combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumabSemin Arthritis Rheum4775776420182915766910.1016/j.semarthrit.2017.10.022AggarwalBBSignalling pathways of the TNF superfamily: A double-edged swordNat Rev Immunol374575620031294949810.1038/nri1184HolnthonerWBonstinglCHromadaCMuehlederSZipperleJStojkovicSRedlHWojtaJSchöchlHGrillariJEndothelial cell-derived extracellular vesicles size-dependently exert procoagulant activity detected by thromboelastometrySci Rep7370720172862336010.1038/s41598-017-03159-0HoriuchiTMitomaHHarashimaSTsukamotoHShimodaTTransmembrane TNF-alpha: Structure, function and interaction with anti-TNF agentsRheumatology (Oxford)491215122820102019422310.1093/rheumatology/keq031ChenXOppenheimJJContrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunityFEBS Lett5853611361820112151371110.1016/j.febslet.2011.04.025YamagishiSOhnishiMPawankarRIL-1 and TNF-alpha-mediated regulation of IL-6, IL-8, and GM-CSF release from cultured nasal epithelial cellsNihon Jibiinkoka Gakkai Kaiho10382983520001094655610.3950/jibiinkoka.103.829(In Japanese)FioccoUSfrisoPOlivieroFLunardiFCalabreseFScaglioriECozziLDi MaggioANardacchioneRMolenaBBlockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkersJoint Bone Spine8016517020132286797510.1016/j.jbspin.2012.06.016BevaartLVervoordeldonkMJTakPPEvaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis?Arthritis Rheum622192220520102050632210.1002/art.27503MonachPABenoistCMathisDThe role of antibodies in mouse models of rheumatoid arthritis, and relevance to human diseaseAdv Immunol8221724820041497525810.1016/S0065-2776(04)82005-4HassanSMilmanUFeldJEderLLaviICohenSZismanDEffects of anti-TNF-α treatment on lipid profile in rheumatic diseases: An analytical cohort studyArthritis Res Ther1826120162783279710.1186/s13075-016-1148-1MaXXuSTNF inhibitor therapy for rheumatoid arthritisBiomed Rep117718420132464891510.3892/br.2012.42BourneTFossatiGNesbittAA PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: Exploring a new mechanism of actionBioDrugs2233133720081877811410.2165/00063030-200822050-00005CapriaADe NardoDBaffettiFRBarbiniUVioloATondoTFontanaLLong-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: The biological coherence between synovial and endothelial inflammationInt J Immunopathol Pharmacol2325526220102037801110.1177/039463201002300123TamLSKitasGDGonzalez-GayMACan suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?Rheumatology (Oxford)531108111920142450124510.1093/rheumatology/ket454MoelantsEAMortierAVan DammeJProostPRegulation of TNF-α with a focus on rheumatoid arthritisImmunol Cell Biol9139340120132362880210.1038/icb.2013.15LisKKuzawińskaOBalkowiec-IskraETumor necrosis factor inhibitors-state of knowledgeArch Med Sci101175118520142562485610.5114/aoms.2014.47827RadnerHAletahaDAnti-TNF in rheumatoid arthritis: An overviewWien Med Wochenschr1653920152565194510.1007/s10354-015-0344-yvan SchouwenburgPARispensTWolbinkGJImmunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNat Rev Rheumatol916417220132339969210.1038/nrrheum.2013.4DommaschEGelfandJMIs there truly a risk of lymphoma from biologic therapies?Dermatol Ther2241843020091984571910.1111/j.1529-8019.2009.01258.xWolfeFMichaudKBiologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational studyArthritis Rheum562886289520071772929710.1002/art.22864BullockJRizviSAASalehAMAhmedSSDoDPAnsariRAAhmedJRheumatoid arthritis: A brief overview of the treatmentMed Princ Pract2750150720183017321510.1159/000493390KallioliasGDLiossisSNThe future of the IL-1 receptor antagonist anakinra: From rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritisExpert Opin Investig Drugs1734935920081832123410.1517/13543784.17.3.349RamírezJCañeteJDAnakinra for the treatment of rheumatoid arthritis: A safety evaluationExpert Opin Drug Saf1772773220182988321210.1080/14740338.2018.1486819BresnihanBNewmarkRRobbinsSGenantHKEffects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trialJ Rheumatol3111031111200415170922ArakiMMatsuokaTMiyamotoKKusunokiSOkamotoTMurataMMiyakeSAranamiTYamamuraTEfficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot studyNeurology821302130620142463445310.1212/WNL.0000000000000317ScottLJTocilizumab: A review in rheumatoid arthritisDrugs771865187920172909431110.1007/s40265-017-0829-7SmolenJSBeaulieuARubbert-RothARamos-RemusCRovenskyJAlecockEWoodworthTAltenROPTION InvestigatorsEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo controlled, randomised trialLancet37198799720081835892610.1016/S0140-6736(08)60453-5MainiRNTaylorPCSzechinskiJPavelkaKBröllJBalintGEmeryPRaemenFPetersenJSmolenJDouble-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum542817282920061694778210.1002/art.22033YipRMLYimCWRole of interleukin-6 inhibitors in the management of rheumatoid arthritis. J Clin Rheumatol:. 2019, doi: 10.1097/RHU.0000000000001293 (Online ahead of print).ParkJYPillingerMHInterleukin-6 in the pathogenesis of rheumatoid arthritisBull NYU Hosp Jt Dis65 (Suppl 1)S4S10200717708744ConigliaroPTriggianesePDe MartinoEFontiGLChimentiMSSunziniFViolaACanofariCPerriconeRChallenges in the treatment of rheumatoid arthritisAutoimmun Rev1870671320193105984410.1016/j.autrev.2019.05.007EmeryPPopeJEKrugerKLippeRDeMasiRLulaSKolaBEfficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic reviewAdv Ther351535156320183012864110.1007/s12325-018-0757-2GaffenSLThe role of interleukin-17 in the pathogenesis of rheumatoid arthritisCurr Rheumatol Rep1136537020091977283210.1007/s11926-009-0052-yKasperkovitzPVVerbeetNLSmeetsTJvan RietschotenJGKraanMCvan der Pouw KraanTCTakPPVerweijCLActivation of the STAT1 pathway in rheumatoid arthritisAnn Rheum Dis6323323920041496295510.1136/ard.2003.013276HodesGEMénardCRussoSJIntegrating Interleukin-6 into depression diagnosis and treatmentNeurobiol Stress4152220162798118610.1016/j.ynstr.2016.03.003KhandakerGMPearsonRMZammitSLewisGJonesPBAssociation of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: A population-based longitudinal studyJAMA Psychiatry711121112820142513387110.1001/jamapsychiatry.2014.1332KooJWDumanRSEvidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depressionCurr Opin Investig Drugs10664671200919579172RaisonCLCapuronLMillerAHCytokines sing the blues: Inflammation and the pathogenesis of depressionTrends Immunol27243120061631678310.1016/j.it.2005.11.006SteptoeAHamerMChidaYThe effects of acute psychological stress on circulating inflammatory factors in humans: A review and meta-analysisBrain Behav Immun2190191220071747544410.1016/j.bbi.2007.03.011LiuHLuitenPGEiselULDejongsteMJSchoemakerRGDepression after myocardial infarction: TNF-α-induced alterations of the blood-brain barrier and its putative therapeutic implicationsNeurosci Biobehav Rev3756157220132341570010.1016/j.neubiorev.2013.02.004AbbottRWhearRNikolaouVBethelACoonJTSteinKDickensCTumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxietyJ Psychosom Res7917518420152593535110.1016/j.jpsychores.2015.04.008KamelKMGadAMMansourSMSafarMMFawzyHMVenlafaxine alleviates complete Freund's adjuvant-induced arthritis in rats: Modulation of STAT-3/IL-17/RANKL axisLife Sci226687620193092840610.1016/j.lfs.2019.03.063SongLQuanXSuLWangKWangHWuLChenCLiSXiangWChenLZhouJInflammation and behavioral symptoms in preoperational glioma patients: Is depression, anxiety, and cognitive impairment related to markers of systemic inflammation?Brain Behav10e0177120203279015410.1002/brb3.1771LuDYLeungYMSuLPInterferon-α induces nitric oxide synthase expression and haem oxygenase-1 down-regulation in microglia: Implications of cellular mechanism of IFN-α-induced depressionInt J Neuropsychopharmacol1643344420132271733210.1017/S1461145712000338CarbonilMcCarthyDJDelafontBFilosiMIvanchenkoERattiELearnedSMAlexanderRDomeniciEBiomarkers for response in major depression: Comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studiesTransl Psychiatry918220193137565910.1038/s41398-019-0521-7SimenBBDumanCHSimenAADumanRSTNFalpha signaling in depression and anxiety: Behavioral consequences of individual receptor targetingBiol Psychiatry5977578520061645826110.1016/j.biopsych.2005.10.013TelferJFBrockJHProinflammatory cytokines increase iron uptake into human monocytes and synovial fibroblasts from patients with rheumatoid arthritisMed Sci Monit10BR91BR95200415039637JenkinsJKHardyKJMcMurrayRWThe pathogenesis of rheumatoid arthritis: A guide to therapyAm J Med Sci32317118020021200337110.1097/00000441-200204000-00002De SimoneVFranzèERonchettiGColantoniAFantiniMCDi FuscoDSicaGSSileriPMacDonaldTTPalloneFTh17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growthOncogene343493350320152517440210.1038/onc.2014.286KatoHEndresJFoxDAThe roles of IFN-γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblastsMod Rheumatol231140115020132330642610.1007/s10165-012-0811-xCampbellJCiesielskiCJHuntAEHorwoodNJBeechJTHayesLADenysAFeldmannMBrennanFMFoxwellBMA novel mechanism for TNF-alpha regulation by p38 MAPK: Involvement of NF-kappa B with implications for therapy in rheumatoid arthritisJ Immunol1736928693720041555718910.4049/jimmunol.173.11.6928De CesarisPStaraceDRiccioliAPadulaFFilippiniAZiparoETumor necrosis factor-alpha induces interleukin-6 production and integrin ligand expression by distinct transduction pathwaysJ Biol Chem273756656711998951645910.1074/jbc.273.13.7566
Role of activated lymphocytes, monocytes, fibroblasts in the pathogenesis of rheumatoid arthritis. IL, interleukin; GM-CSF, granulocyte-macrophage colony-stimulating factor; TNF-α, tumor necrosis factor-α.
JAK/STAT3 signaling pathway mediates the role of cytokines. JAK, Janus kinase; IFN-γ, interferon-γ; IL, interleukin; TNF-α, tumor necrosis factor-α; RA, rheumatoid arthritis.
SPAK/MAPK signaling pathway mediates the role of cytokines. IL, interleukin; TNF-α, tumor necrosis factor-α; RA, rheumatoid arthritis.
Anti-cytokine based therapeutic options for treatment of rheumatoid arthritis.